Edwards Lifesciences Comments on U.S. Appeals Court Order IRVINE, CA -- (Marketwired) -- 04/21/14 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced that the U.S. Court of Appeals for the Federal Circuit today issued a stay for the preliminary injunction that was ordered on April 11 to limit the sale of Medtronic's CoreValve system in the United States. According to the court's two-to-one decision, the injunction has been placed on hold "pending further notice." "We have always made every effort to ensure patients receive the treatment they need and will continue to seek a durable solution that benefits physicians and their patients. We're proud of the track record and large amount of clinical data supporting the performance of the SAPIEN family of valves, making them the preferred choice for doctors treating their patients around the world," said Michael A. Mussallem, Edwards' chairman and CEO. Today's order postpones the implementation of the preliminary injunction. It does not reverse the federal jury's finding of Medtronic's willful infringement, for which all appeals have been exhausted, and does not affect the determination of additional damages. About Edwards Lifesciences Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at www.edwards.com. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, Mr. Mussallem's comments. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statem ent to reflect events or circumstances after the date of the statement. Forward-looking statements involve risks and uncertainties that could cause the roll-out and benefits of the technology to differ materially from those expressed or implied by the forward-looking statements based on a number of factors including but not limited to unexpected outcomes after expanded clinical experience, unexpected changes or delays related to product supply, quality and availability, or unanticipated delays or outcomes in regulatory approvals and decisions. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2013. Edwards, Edwards Lifesciences, the stylized E logo and SAPIEN are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. Media Contact: Sarah Huoh 949-250-5070 Investor Contact: David K. Erickson 949-250-6826
Edwards Lifesciences Comments on U.S. Appeals Court Order
Press spacebar to pause and continue. Press esc to stop.